Table 1.
Comparison of clinical and pathological features between a group with PSA nadir after radiotherapy of ≤ 0.02 ng/ml and that with > 0.02 ng/ml
| Factors | Total (n = 216) | nPSA ≤ 0.02 (n = 196) | nPSA > 0.02 (n = 20) | p |
|---|---|---|---|---|
| Median (range) | Median (range) | Median (range) | ||
| Age, years | 70 (53-86) | 70 (53-86) | 69 (54-77) | 0.080 |
| Initial PSA, ng/ml | 24 (3-338) | 23 (3-337) | 28 (5-167) | 0.288 |
| Neoadjuvant ADT, months | 12 (4-74) | 12 (4-74) | 12 (7-17) | 0.358 |
| Follow-up, months | 84 (12-126) | 84 (12-126) | 81 (13-119) | 0.271 |
| n(%) | n (%) | n (%) | ||
| Gleason score | 0.950 | |||
| ≤ 6 | 24 (11) | 21 (11) | 3 (15) | |
| 7 | 102 (47) | 94 (48) | 8 (40) | |
| 8-10 | 90 (42) | 81 (41) | 9 (45) | |
| T stage (2009) | 0.040 | |||
| 1c-2a | 55 (26) | 51 (26) | 4 (20) | |
| 2b-2c | 48 (22) | 45 (23) | 3 (15) | |
| 3a | 75 (35) | 71 (36) | 4 (20) | |
| 3b | 35 (16) | 28 (14) | 7 (35) | |
| 4 | 3 (1) | 1 (1) | 2 (10) | |
| Biopsy positive core rate | 0.036 | |||
| < 34% | 71 (32) | 68 (35) | 3 (15) | |
| 34-67% | 77 (36) | 70 (36) | 7 (35) | |
| > 67% | 65 (30) | 55 (27) | 10 (50) | |
| Unknown | 3 (2) | 3 (2) | 0 (0) |
nPSA – PSA nadir after radiotherapy, PSA – prostate-specific antigen, ADT – androgen deprivation therapy